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Abstract: Driving a car is important to maintain independence and participate in society. 
Many of those who use psychoactive medication are outpatients and are thus likely to drive 
a vehicle. Most common adverse effects that impair driving are reduced alertness, affected 
psychomotor functioning and impaired vision. This review discusses the effects on driving 
ability  of  most  commonly  prescribed  psychoactive  drugs,  including  hypnotics, 
antidepressants, antihistamines, analgesics and stimulant drugs. Within these categories of 
medicines significant differences concerning their impact on driving ability are evident. The 
International Council on Alcohol, Drugs and Traffic Safety (ICADTS) categorization can 
help physicians to make a choice between treatments when patients want to drive a car. 
Keywords: Driving; drugs; psychoactive medication; traffic safety; ICADTS. 
 
 
1. Introduction 
 
Psychoactive drugs, i.e. drugs that exert their activity on the Central Nervous System, and drugs 
that affect motor function are of concern when it comes to traffic safety. Since the vast majority of 
those  who  use  psychoactive  medication  are  outpatients,  it  is  reasonable  to  assume  that  they  also 
participate in traffic. Roadside surveys estimate the incidence of drivers who are under the influence of 
psychoactive  drugs  at  between  5%  and  35%  [1].  Given  the  worldwide  increase  in  prescribing  of 
psychoactive medication [2], traffic safety is an issue that’s becoming increasingly relevant. Yearly, 
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increasing numbers of traffic deaths are reported. Although in the U.S.A. and Europe a significant 
reduction in traffic accidents is evident, in other parts of the world (e.g. Africa and Southeast Asia) the 
number of traffic accidents has increased dramatically. In this context, the World Health Organization 
dedicated the 2004 World Health Day to road safety [3]. This review updates on the effects on driving 
performance of the most commonly prescribed psychoactive drugs.  
 
2. Methodology 
 
There  are  various  methods  to  examine  driving  ability  and  assess  the  effects  of  psychoactive 
medication on traffic safety. Epidemiological studies provide evidence about the (increased) risk of 
becoming  involved  in  traffic  accidents  when  using  psychoactive  medication.  Although  this  is 
important information, it is gathered after accidents have happened. Ideally, one would like to have 
this information beforehand in order to prevent driving under the influence of these drugs. A limitation 
of most epidemiological studies is that the statistical analysis is based on groups of drugs instead of 
individual drugs. This is unfortunate, because within drug groups the effects of individual drugs on 
driving  ability  can  differ  significantly.  Many  researchers  use  laboratory  tests  to  examine  driving 
related skills and abilities such as reaction speed, working memory and psychomotor functioning. 
Although these skills and abilities are all of great importance to operating a vehicle it has been proven 
that it is very difficult to predict actual driving performance from these tests [4]. This is caused by the 
fact that these skills and abilities are tested in isolation, whereas in real driving they are integrated and 
performed simultaneously.  Also,  the extent of impairment  of individual skills  and abilities differs 
greatly after administration of a psychoactive drug [5]. This is illustrated by Figure 1, showing the 
blood alcohol concentrations (BAC) at which different skills and abilities become impaired.  
 
Figure  1.  Skills  and  abilities  related  to  driving  and  corresponding  blood  alcohol 
concentrations at which more than half of behavioral tests show significant impairment [5]. 
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Driving simulators are popular to test driving skills. They are safe because no real traffic is involved 
and tests can be performed in a controlled environment. Traditional driving simulators were often very 
simple divided attention tasks. Equipment regularly  consisted of a steering wheel and a computer 
screen. Subjects had to perform a tracking task and reaction speed task simultaneously, mimicking two 
important driving skills. Unfortunately, no other traffic was involved and often no road scenery was 
depicted on the computer screen. Therefore, these driving simulators had little predictive validity for 
real driving [6]. The vital lacking element of other traffic has been introduced in most current driving 
simulators. Equipment of these sophisticated driving simulators often comprises a real car, a wide 
screen, and road scenery involving other traffic that interacts with the subject. This set-up is a great 
improvement when compared to the first generation of driving simulators. Nevertheless, it remains to 
be determined to what extent driving simulators predict actual driving in real traffic. Subjects who 
perform a driving simulator test are aware of the artificial environment and this may have a significant 
impact on their driving style and performance. 
Given legislative restrictions of most countries, relatively few studies have been performed in real 
traffic. Methods to determine driving performance were often limited to subjective ratings of driving 
instructors or researchers and self reports by patients. The subjective nature of these measurements 
makes it difficult to compare different drugs or dosages. To establish this, objective measurement of 
the magnitude of impairment is essential. One test that does measure driving performance objectively 
is the standardized on-the-road driving test in real traffic. Over the past 30 years, many psychoactive 
drugs have been examined using this test. The methodology of the driving test, applied only in The 
Netherlands to examine psychoactive medication, will be described below and results from studies 
applying this test are summarized in this review.  
 
2.1. The On-the-Road Driving Test 
 
The on-the-road driving test in real traffic was developed in the 1980s [7] and has been applied in 
over 50 studies to determine the effects of psychoactive drugs on driving ability. The test has been 
highly standardized and has shown to be sensitive to dose-dependent impairment after administration a 
variety of psychoactive drugs including hypnotics, anxiolytics, antidepressants, analgesics, stimulants, 
and antihistamines. In the standardized driving test, subjects are instructed to drive a car over a 100-km 
(61 miles) highway while maintaining a constant speed (58 miles/h) and a steady lateral position 
within the right (slower) traffic lane. The primary parameter of the test is the Standard Deviation of 
Lateral Position (SDLP, cm): the weaving of the car. This is shown in Figure 2. It is evident from this 
Figure that SDLP represents the amount of vehicle control. Higher SDLP values represent increased 
weaving of the car.  
A camera, mounted on the roof of the car, continuously records the position of the car within the 
right traffic lane, by tracking the relative distance of the car from the delineation in the middle of the 
road. This is illustrated in Figure 3. In the right front seat, a licensed driving instructor accompanies 
the subject. His main responsibility is to guard safety during the driving test, and he is equipped with a 
brake and clutch system. If the subject or the driving instructor judges that it is unsafe to continue 
driving, the test is terminated before completion and the driving instructor transports the subject back 
to the Institute. Int. J. Environ. Res. Public Health 2009, 6                 
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Figure 2. Standard Deviation of the Lateral Position, SDLP. Increased weaving of the car 
(higher SDLP values) represents reduced vehicle control and may result in  out of lane 
excursions. 
                
 
Figure 3. The instrumented car. 
 
Note that the camera for lateral position measurements is equipped with two infrared lights, to 
enable recording during the night and dark weather circumstances. Adapted with permission from 
reference [12]. 
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2.2. ICADTS Categorization 
 
The  categorization  system  of  the  International  Council  on  Alcohol,  Drugs  and  Traffic  Safety 
(ICADTS) will be used to indicate whether or not it is safe to drive a car when using a specific 
psychoactive drug [8]. Drugs are allocated to one of the following categories:  
1. Presumed to be safe or unlikely to produce an effect; 
2.  Likely to produce minor or moderate adverse effects; 
3. Likely to produce severe effects or presumed to be potentially dangerous. 
To make the categories understandable, a comparison with blood alcohol concentration (BAC) is 
made. Driving impairment for the categories I, II and III are equivalent to BAC < 0.5 g/L (<0.05%), 
BAC  0.5-0.8  g/L  (0.05-0.08%),  and  BAC  >  0.8  g/L  (>0.08%),  respectively.  Description  and 
interpretation of the categories is summarized in Box 1. 
 
Box 1. Description of ICADTS category Interpretation and practical use.  
Category I: Presumed to be safe or unlikely to produce an effect 
 
In  various  experimental  circumstances  negligible  or  no  impairment  of  driving  performance  or 
performance related to driving is repeatedly demonstrated. Also for medicinal drugs that are presumed 
not to be dangerous based on their pharmacological profile, even though there are no experimental 
studies that support this presumption. For the most frequently used drugs in this category the effect has 
been assessed in over-the-road driving tests as equivalent to blood alcohol concentrations < 0.5 g/L 
(<0.05%). 
 
Advice for the patient: Be careful not to drive before having read the warnings in the package insert. 
 
Category II: Likely to produce minor or moderate adverse effects 
 
Some  impairment  of  driving  performance  or  performance  related  to  driving  is  seen  in  various 
experimental laboratory circumstances. Also for drugs that will not produce severely adverse effects, 
but  because  of  a  lack  of  sufficient  experimental  studies  it  can  not  be  established  if  the  effect  is 
moderate, light or absent. For the most frequently used drugs in this category the effect has been 
assessed in over-the-road driving tests as equivalent to blood alcohol concentrations 0.5- 0.8 g/L (0.05-
0.08%).  
 
Advice for the patient: Do not drive without consulting a healthcare professional about the possible 
impairing effects. 
 
Category III: Likely to produce severe effects or presumed to be potentially dangerous 
 
In  various  experimental  circumstances  gross  impairment  of  driving  performance,  or  performance 
related to driving, is repeatedly seen. Also for drugs presumed to be potentially dangerous based upon 
their pharmacological profile, but there are not 
sufficient experimental studies to support this presumption. For the most frequently used drugs in this 
category the effect has been assessed in over-the-road driving tests as equivalent to blood alcohol 
concentrations > 0.8 g/L (>0.08%). 
 
Advice for the patient: Do not drive when this drug is taken and consult a healthcare professional when 
to start driving again after evaluation of the treatment outcomes. Int. J. Environ. Res. Public Health 2009, 6                 
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The effect of different BAC levels on driving performance was determined in 24 social drinkers [9]. 
A  dose-dependent  impairment  was  observed.  SDLP  increments  after  alcohol  consumption 
corresponding to the most common legal limits for driving were +2.4 cm (0.05%), +4.1 cm (0.08%), 
and +5.3 cm (0.10%) and are often used as reference values to illustrate driving safety when using 
psychoactive drugs. The study revealed a steady correlation between BAC and SDLP.  
 
3. CNS Drugs and Traffic Safety 
 
The  following  sections  discuss  the  effects  on  driving  ability  of  the  most  commonly  used 
psychoactive drugs, including hypnotics, anxiolytics, antidepressants, antihistamines, analgesics and 
stimulant drugs. 
 
3.1. Hypnotics / Sleep Medication 
 
Several studies have examined the residual effects of benzodiazepine hypnotics on driving ability 
[10-12]. In these studies, hypnotic drugs were taken at bedtime for 1 or 2 nights. The driving tests were 
performed the following morning (10-11 hours after intake) and in the afternoon (16-17 hours after 
intake), corresponding to the times one drives to and from work. Increment relative to placebo for 
benzodiazepine hypnotics are shown in Figure 4.  
 
Figure 4. Benzodiazepine hypnotics and driving performance. 
 
Standard Deviation of Lateral Position (SDLP) increments relative to placebo are shown. Driving 
tests were performed in the morning (dark blue bars) and afternoon (light blue bars) (10–11 and 
16–17  h  after  bedtime  administration,  respectively).  Significant  differences  from  placebo  are 
indicated  by  an  asterisk,  orange  lines  indicate  levels  of  SDLP  increment  observed  with  most 
common legal blood alcohol limits for driving a car. NIT, Nitrazepam; LOR, lormetazepam; TEM, 
temazepam; LOP, loprazolam; FLN, flunitrazepam; FLU, flurazepam, SEC = secobarbital, caps = 
capsules, tabs = tablets, BAC = blood alcohol concentration. 
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Figure 4 shows that benzodiazepine hypnotics significantly impair driving performance. Driving 
impairment  was  most  pronounced  in  the  morning.  In  the  afternoon,  driving  impairment  was  less 
evident and absent for short-acting benzodiazepines. For long-acting benzodiazepines driving was also 
impaired in the afternoon; especially when using higher dosages than recommended. To illustrate the 
magnitude of driving impairment, effects of different dosages of alcohol are also depicted in Figure 3. 
Most benzodiazepine hypnotics were categorized in ICADTS category II or III (see Table 1). 
 
Table 1. ICADTS classification of commonly prescribed hypnotics and sedative drugs [8]. 
Substance name  Category 
Barbiturates 
Secobarbital  III 
Benzodiazepine derivatives   
Flurazepam  III 
Nitrazepam  III 
Flunitrazepam  III 
Estazolam  III 
Triazolam  III 
Lormetazepam  III 
Temazepam  III 
Midazolam  III 
Brotizolam  III 
Quazepam  III 
Loprazolam  III 
Benzodiazepine related drugs 
Zopiclon  III 
Zolpidem  II 
       
The Z-drugs zopiclone, zolpidem and zaleplon were developed to overcome the unwanted residual 
effects  of  benzodiazepine  hypnotics.  Unfortunately,  the  introduction  of  zopiclone  was  no 
improvement. Several on-the-road studies showed pronounced driving impairment after consumption 
of zopiclone. SDLP increments ranged between 3 and 8 cm, comparable to impairment observed for 
blood alcohol concentrations of 0.05% to 0.10% (above the legal limit for driving in many countries). 
Zolpidem, when taken as recommended, has no residual effects on driving ability and thus is a great 
improvement when compared to benzodiazepines and zopiclone. However, when shortening the time 
between intake and driving dose-dependent impairment is evident [13]. Also, various accidents and 
impaired driving have been reported after inappropriate use of zolpidem [14]. Zaleplon has no negative 
residual effects on driving ability. Even when taken in the middle of the night  four hours before 
driving, twice the recommended dose of zaleplon did not affect driving performance.  Results from 
epidemiological studies confirm that benzodiazepines and zopiclone significantly increase the risk of 
becoming  involved  in  traffic  accidents  [10-11,15].  New  hypnotics  with  different  mechanisms  of 
action, such as those acting at melatonin or serotonin receptors, are both promising and needed for 
those patients who have to use hypnotic drugs and want to participate safely in traffic. Int. J. Environ. Res. Public Health 2009, 6                 
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3.2. Anxiolytics 
 
Up  to  50%  of  the  patients  visiting  their  physician  suffer  from  anxiety  disorders,  including 
generalized  anxiety  disorder,  panic  disorder,  post-traumatic  stress  disorder,  obsessive-compulsive 
disorder, social anxiety disorder, or phobias. A substantial number of those patients use anxiolytics 
including benzodiazepines, tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors 
(SSRIs),  or  buspirone.  Their  effects  on  driving  ability  have  been  extensively  studied  and  results 
supported by epidemiological evidence [16]. 
Both  benzodiazepines  and  TCAs  significantly  impaired  driving  performance  after  single  dose 
administration. Impairment of benzodiazepines when used as anxiolytic is much more pronounced 
when compared to impairment when used as hypnotic drug. This difference is caused by the fact that 
the time between drug intake and the driving test is much greater for hypnotics (10-11 hours) when 
compared to anxiolytics (1 hour). The different time intervals were chosen to reflect normal use of 
anxiolytics (during the day, for example after awaking) and hypnotics (at bedtime).  
Tolerance develops slowly and after a week of daily treatment with benzodiazepine anxiolytics 
driving remained significantly impaired [16]. This effect was less pronounced for TCAs. In contrast, 
SSRIs, 5HT-antagonists and buspirone produced no significant impairment on the driving test after 
both  acute  and  repeated  administration.  Corresponding  ICADTS  categories  of  most  commonly 
prescribed anxiolytics are summarized in Tables 2 and 3. 
 
Table 2. ICADTS classification of anxiolytic drugs [8]. 
Substance name  Category 
Benzodiazepine derivatives 
Diazepam  III 
Chlordiazepoxide  III 
Medazepam  II 
Oxazepam  III 
Lorazepam         III 
Bromazepam     III 
Clobazam  II 
Ketazolam  III 
Alprazolam  III 
Azaspirodecandione derivatives 
Buspirone   I 
 
Table 3. ICADTS classification of commonly prescribed antidepressants [8]. 
Substance name  Category 
Non-selective monoamine reuptake inhibitors 
Desipramine  II 
Imipramine  II 
Clomipramine  II 
Amitriptyline  III Int. J. Environ. Res. Public Health 2009, 6                 
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Table 3. Cont. 
Nortriptyline  II 
Doxepin  III 
Selective serotonin reuptake inhibitors 
Fluoxetine  I 
Citalopram  II 
Paroxetine  I 
Sertraline  II 
Fluvoxamine  II 
Escitalopram  II 
Monoamine oxidase A inhibitors 
Moclobemide  II 
Other antidepressants 
Mianserin  III 
Trazodone  III 
Nefazodone  II 
Mirtazapine  III 
Venlafaxine  I 
Reboxetine  I 
             
Tables 2 and 3 clearly show that benzodiazepine anxiolytics and TCAs (listed as category II and III 
drugs) are regarded as more dangerous than SSRIs and related compounds (listed as category I drugs). 
 
3.3. Antidepressants 
 
The  effects  of  most  commonly  used  antidepressants  on  driving  ability  have  been  investigated 
applying the on-the-road test [17]. Driving after intake of TCAs (including amitriptyline, doxepine and 
imipramine), mianserin and mirtazapin was significantly impaired after treatment initiation. Tolerance 
developed  gradually,  and  after  1  week  of  treatment  driving  impairment  was  absent  or  much  less 
pronounced.  Nocturnal  treatment  with  these  antidepressants  did  not  affect  next  day  driving 
performance.  In  contrast  to  the  TCAs,  SSRIs  (including  fluoxetine,  paroxetine  and  escitalopram), 
related antidepressants (venlafaxine and nefazodone), and moclobemide showed no significant effect 
on driving performance. The ICADTS categorization of most commonly used antidepressant drugs is 
summarized in Table 3. 
 
3.4. Antihistamines 
 
All antihistamines are capable of crossing the blood-brain barrier and thus may cause sedation. 
Most commonly used antihistamines have been examined using the on-the-road test [18]. Over the past 
decades  3  generations  of  antihistamines  have  been  developed,  each  improving  his  proceeding 
generation in terms of less sedation and adverse effects.  
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Table 4. ICADTS classification of commonly prescribed antihistamines [8]. 
Substance name  Category 
Aminoalkyl ethers 
Diphenhydramine  III 
Clemastine  III 
Substituted alkylamines 
Dexchlorpheniramine  II 
Chlorphenamine  II 
Pheniramine  II 
Phenothiazine derivatives 
Promethazine  III 
Mequitazine  II 
Piperazine derivatives 
Meclozine  II 
Cetirizine  II 
Levocetirizine  I 
Other antihistamines for systemic use 
Triprolidine  III 
Terfenadine  I 
Loratadine  I 
Azelastine  I 
Ebastine  I 
Mizolastine  II 
Fexofenadine  I 
Desloratadine  I 
 
The  oldest  (first-generation)  antihistamines  (diphenhydramine,  triprolidine,  terfenadine, 
dexchlorpheniramine, clemastine) significantly impair driving performance after both one-time and 
repeated  (daily)  administration.  Second-generation  antihistamines  (cetirizine,  loratadine,  ebastine, 
mizolastine,  acrivastine,  emedastine,  mequitazine)  may  also  impair  driving  performance,  but  this 
differs  greatly  among  individuals.  The  magnitude  and  extent  of  impairment  depends  on  the 
administered dose, sex, and time between  driving and treatment administration. Tolerance develops 
after  four  to  five  days  of administration, but impairment is not  always  absent.  In contrast, third-
generation  antihistamines  (fexofenadine,  desloratadine,  and  levocetirizine)  produce  no  driving 
impairment after both one-time and  repeated administration.  The  ICADTS categorization of most 
commonly used antihistamines is summarized in Table 4. 
 
3.5. Analgesics 
 
Pain itself can significantly impair driving performance [19]. Effective treatment with Non-steroidal 
anti-inflammatory drugs (NSAIDs) or opioids may (partially) relieve the pain. Up to now, only few 
driving studies have been performed with analgesics. Laboratory tests of cognitive functioning and 
psychomotor  skills  generally  do  not  show  significant  performance  impairment  in  patients  using 
NSAIDs or acetaminophen. Therefore they are listed in ICADTS category I. One driving study [20] 
examined the effects on driving of bromfenac. This NSAID, which is no longer marketed, did not Int. J. Environ. Res. Public Health 2009, 6                 
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affect driving or related skills. The same study also examined the opioid oxycodone. No significant 
differences from placebo were found, but subjects indicated that much more effort was needed to 
perform the driving test. Laboratory studies failed to find consistent results when testing opioids [21]. 
Nevertheless, ICADTS categorizes many opioid analgesics in class II (e.g., oxycodone, and codeine) 
or III (e.g. morphine, tramadol and fentanyl). Opioids show a strong dose-dependent impairing effect 
on performance and after treatment initiation dosages are often gradually increased. This may interfere 
with developing tolerance to their impairing effects, and thus these drugs are often grouped in category 
II or III. 
Chronic pain patients are often treated with antidepressants such as amitriptyline instead of opioids 
and  NSAIDs.  Thirteen  hours  after  treatment  administration,  amitriptyline  (25  mg)  significantly 
impaired on-the-road driving performance in chronic neuropathic pain patients [22]. After two weeks 
of daily use, tolerance developed to the impairing effects of amitriptyline. 
 
3.6. Stimulant Drugs 
 
Stimulant drugs are used in the treatment of attention deficit hyperactivity disorder (ADHD) and 
narcolepsy. Purpose of using these drugs is to improve attention and daytime alertness. Two studies 
showed improvement of driving performance after stimulant drug use.  
Ramaekers  and  colleagues  [23]  examined  the  effects  of  3-4-methylendioxymethamphetamine 
(MDMA) (75 mg), methylphenidate (20 mg) and placebo on driving performance in 18 recreational 
MDMA users. The on-the-road driving test and a car following test were performed three to five hours 
after drug use, and the next day (27 to 29 hours after intake) to examine possible withdrawal effects. 
Both  MDMA  and  methylphenidate  significantly  improved  driving  performance  as  indicated  by 
reduced  weaving.  However,  MDMA  negatively  affected  performance  in  the  car  following  test, 
whereas performance after using methylphenidate did not differ significantly from placebo. During 
withdrawal, no significant differences from placebo were found. Verster and colleagues [24] examined 
the effects of methylphenidate on driving performance in adults with ADHD. After a training session 
and withdrawal of methylphenidate for at least four days, patients participated in a double blind trial 
and  performed  an  on-the-road  driving  test  after  intake  of  placebo  or  their  regular  dose  of 
methylphenidate. In line with Ramaekers’ findings, driving performance after using methylphenidate 
was significantly improved when compared to placebo. 
 
4. Conclusions 
 
Various psychoactive drugs  affect  driving performance. These effects  are most prominent  after 
treatment initiation and tolerance develops after chronic use. Impairment further depends on dose and 
half-life of a drug, time after administration, gender and age.  
Limitations of current driving research include the fact that they have not examined driving in 
patients who chronically use psychoactive medication. Epidemiological data show that after long-term 
use of psychoactive medication tolerance develops to the impairing effects of these drugs. Patients get 
used to the adverse effects of drugs, and gradually they wear off as do the risks of traffic accidents 
[25]. Tolerance develops slowly and is much less likely to develop after intermittent (as-needed) use. Int. J. Environ. Res. Public Health 2009, 6                 
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For example, increased traffic accident risks for users of benzodiazepine hypnotics have been reported 
after one year of chronic use [10,11]. Unfortunately, on-the-road studies have focused primarily on 
short term use (i.e. one day to two weeks). One study did examine the effects of four weeks daily 
treatment  with  diazepam  [26]  and  confirmed  that  tolerance  develops  slowly.  After  four  weeks  of 
treatment  with  diazepam  SDLP  increment  was  still  significantly  increased.  Nevertheless, 
epidemiological studies have shown no significant increase in traffic accident risk after chronic use  
(> 1 year) of other psychoactive drugs such as opioids [27]. 
A second limitation is that individual differences between patients are often not taken into account. 
Most drugs are supplied in a standardized dose, not taking into account age, gender and metabolism of 
individual users. However, these factors are important in determining the presence and magnitude of 
adverse effects. In some driving studies – but not in general, it has been shown that SDLP increment in 
women is significantly greater than in men [28]. Also, elderly often perform worse when compared to 
healthy young adults [29]. In this context, it is unfortunate that most experimental studies have been 
conducted in healthy male young adults, whereas patients using psychoactive medication are often 
female elderly.  
Future  pharmaceutical  research  should  focus  on  developing  new  psychoactive  medication  that 
produces less sedation and adverse effects. These new drugs should be tested preferably in healthy 
volunteers followed by studies in patients who actually need the medication. Effects on driving ability 
after long-term use should be examined as well. 
Finally, for many diseases a number of different treatment options are available. In terms of traffic 
safety, physicians  should choose medication that has  shown to  be devoid  of impairing effects on 
driving ability. The ICADTS categorization can help them in making this decision. 
 
Disclaimer  
 
Although the information presented below has been gathered and evaluated with great care, the 
authors will not accept  any liability after use of the information by patients taking  the medicines 
discussed. Patients should always consult their physician concerning whether or not it is safe to drive a 
car. 
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